Harmonization of summaries of product characteristics (SmPCs) of drugs with the same active ingredients: an evaluation of SmPCs of the most frequently prescribed active substances
Open Access
- 27 October 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (3) , 419-434
Abstract
Purpose: In aut-idem or generic substitution, discrepancies between summaries of product characteristics (SmPCs) referring to the same active substance (AS) may cause difficulties regarding informed consent and medical liability. The qualitative and quantitative characteristics of such discrepancies are insufficiently studied, impeding harmonization of same-substance SmPCs and compromising safe drug treatment. Methods: SmPCs of the one hundred most frequently prescribed ASs in Germany were analyzed for discrepancies in the presentation of indications (Inds) and contraindications (CInds). Inclusion and exclusion criteria of drugs/SmPCs were chosen according to the standards of the aut-idem substitution in Germany. Results: According to the study protocol, we identified 1486 drugs, of which 1426 SmPCs could be obtained. 41% respectively 65% of the ASs had same-substance SmPCs that differed from the respective reference SmPC in the number of listed Inds respectively CInds. The number of listed Inds/CInds varied considerably between same-substance SmPCs with maximum ranges in Inds of 7 in amoxicillin, and in CInds of 11 in lisinopril. Many ASs had large proportions (> 50%) of associated same-substance SmPCs that differed from the respective reference SmPC. A considerable proportion of ASs had same-substance SmPCs with formal and content-related differences other than the discrepancy in the number of Inds/CInds. Conclusion: This evaluation of same-substance SmPCs shows a clear lack of harmonization of same-substance SmPCs. Considering that generic substitution has become the rule and that physicians usually do not know which drug the patient receives in the pharmacy, these discrepancies raise several questions, that require a separate legal evaluation.Keywords
Funding Information
- Universität Ulm
This publication has 11 references indexed in Scilit:
- Unterschiedliche Anzahl von Kontraindikationen zwischen Fachinformationen wirkstoffgleicher Arzneimittel – eine Analyse von Daten aus Fachinformationen von neuropsychiatrischen ArzneimittelnFortschritte der Neurologie · Psychiatrie, 2019
- Natural language processing‐based assessment of consistency in summaries of product characteristics of generic antimicrobialsPharmacology Research & Perspectives, 2018
- Generic antiepileptic drugs—Safe or harmful in patients with epilepsy?Epilepsia, 2018
- Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System DrugsDrug Safety, 2017
- Arterielle Hyper- und Hypotonie assoziiert mit Psychopharmaka: eine Risikobewertung basierend auf den FachinformationenDMW - Deutsche Medizinische Wochenschrift, 2017
- Therapeutic equivalence of antipsychotics and antidepressants – A systematic reviewPharmacological Reports, 2016
- Rational Use of Generic Psychotropic DrugsCNS Drugs, 2013
- Switching from Brand‐Name to Generic Psychotropic Medications: A Literature ReviewCNS Neuroscience & Therapeutics, 2010
- Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switchingInternational Clinical Psychopharmacology, 2010
- The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugsClinical Therapeutics, 2003